Pleural-Based Lung Mass With Prior Breast Cancer
A 58-year-old woman with a 6-year history of hormone receptor–positive breast cancer presents with a 2.2 cm right lower lobe lung mass abutting the pleura; PET shows moderate uptake, no other lesions. The radiologist calls it 'indeterminate.' The surgeon requests intraoperative frozen section to distinguish organizing pneumonia from carcinoma before completing lobectomy. The wedge biopsy is 1.4 cm and grossly pale and firm; the pathology assistant has embedded one fragment for frozen section and retained the remainder in formalin. The frozen section shows a proliferation of atypical glands in a fibrotic stroma with crush artifact and only rare definite epithelial nests. The surgeon is waiting in the OR. The lab has a 20-minute frozen-section turnaround target and only two unprocessed blocks of lesional tissue remain after the frozen block is cut.
1. What is the most appropriate intraoperative approach, and how should the frozen-section findings be communicated to the surgeon?
Read the worked answer
The frozen section is not definitive. The differential includes organizing pneumonia, primary lung adenocarcinoma, and metastatic breast carcinoma, and the crush artifact plus rare definite epithelial nests make a malignant diagnosis unsafe on frozen section alone. The correct move is to communicate a descriptive, probabilistic diagnosis: atypical glandular proliferation with fibrosis and crush artifact, carcinoma cannot be excluded, and permanent sections with immunohistochemistry are required. Do not force a benign or malignant call merely because the surgeon is waiting. If the planned lobectomy depends on a definitive intraoperative cancer diagnosis, recommend deferring the resection until permanents are available, or at most proceeding with wedge excision if that is oncologically acceptable. Document the conversation and the reason for deferral. Also protect the tissue: the frozen block should not be serially sectioned away, and the two remaining blocks should be handled so that both diagnosis and predictive testing remain possible.
2. Design an immunohistochemical workup using the limited tissue, and explain how you would interpret the likely patterns.
Read the worked answer
Start with a minimal, sequential panel rather than exhausting the block with every possible stain. On the first unstained slides, use TTF-1 and napsin A for lung origin, plus GATA3 and ER for breast origin; add p40 or p63 only if squamous or poorly differentiated morphology is present. A TTF-1/napsin A–positive, GATA3/ER-negative tumor supports primary lung adenocarcinoma. A GATA3/ER-positive, TTF-1/napsin A–negative tumor supports metastatic breast carcinoma. Beware pitfalls: TTF-1 can be positive in small cell carcinoma and occasionally in other tumors; GATA3 is not entirely specific for breast; ER can be weak or absent in metastatic breast cancer. If the first panel is ambiguous, add a second small panel rather than ordering ten stains simultaneously. Reserve at least one block for molecular testing if the tumor proves to be lung adenocarcinoma, and document tumor cellularity before sending tissue out.
3. If permanent sections confirm adenocarcinoma, how should molecular and predictive testing be prioritized without exhausting the specimen?
Read the worked answer
Prioritize by the most likely primary and by actionable results. If the immunophenotype supports lung primary, order PD-L1 and molecular testing for EGFR, ALK, ROS1, BRAF, and KRAS, using the block with the highest tumor cellularity. If the phenotype supports breast metastasis, prioritize ER, PR, and HER2 rather than lung predictive markers. Because only two blocks remain, choose one block for diagnostic IHC and reserve the other for molecular testing; do not cut all slides at once. If tumor cellularity is below the laboratory's validated threshold, request a repeat biopsy or cell block rather than reporting an inadequate molecular result. Communicate the triage plan to oncology and document the tissue stewardship decision, because the treatment pathway changes substantially depending on whether this is a new lung primary or metastatic breast cancer.